



# **Tuberculosis Country Profile 2021 Indonesia**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Indonesia

Population 2020: 274 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	824 000 (755 000-897 000)	301 (276-328)
HIV-positive TB incidence	18 000 (7 700-32 000)	6.5 (2.8-12)
HIV-negative TB mortality	93 000 (84 000-103 000)	34 (31-38)
HIV-positive TB mortality	4 800 (4 300-5 300)	1.8 (1.6-1.9)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	47% (43-51)
TB patients facing catastrophic total costs, 2020	38% (33-44)
TB case fatality ratio (estimated mortality/estimated incidence), 2020	12% (10-14)

## TB case notifications, 2020

Total new and relapse	384 025
- % tested with rapid diagnostics at time of diagnosis	38%
- % with known HIV status	50%
- % pulmonary	91%
- % bacteriologically confirmed <sup>^</sup>	52%
- % children aged 0-14 years	9%
- % women (aged ≥15 years)	38%
- % men (aged ≥15 years)	53%
Total cases notified	393 323

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	7 693	4%
- on antiretroviral therapy	2 592	34%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	58%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	79%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	7 921
Patients started on treatment - MDR/RR-TB <sup>^^^</sup>	5 232
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	293
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>	272
MDR/RR-TB cases tested for resistance to any fluoroquinolone	2 614

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	83%	555 741
Previously treated cases, excluding relapse, registered in 2019	74%	5 574
HIV-positive TB cases registered in 2019	70%	11 575
MDR/RR-TB cases started on second-line treatment in 2018	47%	4 348
XDR-TB cases started on second-line treatment in 2018	30%	83

## TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	3.6% (3.3-3.9)

## TB financing

National TB budget, 2021 (US\$ millions)	515
- Funding source, domestic	20%
- Funding source, international	14%
- unfunded	66%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




## HIV-negative TB mortality

(Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2020

(Number)




## Cases attributable to five risk factors, 2020

(Number)



## Total budget

(US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

<sup>^</sup> Calculated for pulmonary cases only

<sup>^^</sup> Includes cases with unknown previous TB treatment history

<sup>^^^</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed